AU2017283511B2 - Formulation for use in the treatment of uremic pruritus - Google Patents

Formulation for use in the treatment of uremic pruritus Download PDF

Info

Publication number
AU2017283511B2
AU2017283511B2 AU2017283511A AU2017283511A AU2017283511B2 AU 2017283511 B2 AU2017283511 B2 AU 2017283511B2 AU 2017283511 A AU2017283511 A AU 2017283511A AU 2017283511 A AU2017283511 A AU 2017283511A AU 2017283511 B2 AU2017283511 B2 AU 2017283511B2
Authority
AU
Australia
Prior art keywords
histidine
skin
urea
derivative
nucleophile
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017283511A
Other languages
English (en)
Other versions
AU2017283511A1 (en
Inventor
David Evans
Michelle Georgiou
Jesper Lange
Torkil Menne
Johan Selmer
Derek Wheeler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biomee ApS
Original Assignee
Drug Delivery Solutions ApS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Drug Delivery Solutions ApS filed Critical Drug Delivery Solutions ApS
Publication of AU2017283511A1 publication Critical patent/AU2017283511A1/en
Application granted granted Critical
Publication of AU2017283511B2 publication Critical patent/AU2017283511B2/en
Priority to AU2020202785A priority Critical patent/AU2020202785B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2017283511A 2016-06-17 2017-06-16 Formulation for use in the treatment of uremic pruritus Active AU2017283511B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2020202785A AU2020202785B2 (en) 2016-06-17 2020-04-27 Formulation for use in the treatment of uremic pruritus

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA201670438 2016-06-17
DKPA201670438 2016-06-17
DKPA201770225 2017-03-28
DKPA201770225 2017-03-28
PCT/DK2017/050201 WO2017215723A1 (en) 2016-06-17 2017-06-16 Formulation for use in the treatment of uremic pruritus

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2020202785A Division AU2020202785B2 (en) 2016-06-17 2020-04-27 Formulation for use in the treatment of uremic pruritus

Publications (2)

Publication Number Publication Date
AU2017283511A1 AU2017283511A1 (en) 2019-01-17
AU2017283511B2 true AU2017283511B2 (en) 2020-02-06

Family

ID=60663348

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2017283511A Active AU2017283511B2 (en) 2016-06-17 2017-06-16 Formulation for use in the treatment of uremic pruritus
AU2020202785A Active AU2020202785B2 (en) 2016-06-17 2020-04-27 Formulation for use in the treatment of uremic pruritus

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2020202785A Active AU2020202785B2 (en) 2016-06-17 2020-04-27 Formulation for use in the treatment of uremic pruritus

Country Status (11)

Country Link
US (2) US10806721B2 (cg-RX-API-DMAC7.html)
EP (2) EP3471720B1 (cg-RX-API-DMAC7.html)
JP (3) JP7019684B2 (cg-RX-API-DMAC7.html)
KR (3) KR102454777B1 (cg-RX-API-DMAC7.html)
CN (2) CN109414430B (cg-RX-API-DMAC7.html)
AU (2) AU2017283511B2 (cg-RX-API-DMAC7.html)
BR (1) BR112018076229A2 (cg-RX-API-DMAC7.html)
CA (1) CA3026620C (cg-RX-API-DMAC7.html)
ES (1) ES3006940T3 (cg-RX-API-DMAC7.html)
RU (1) RU2018146294A (cg-RX-API-DMAC7.html)
WO (1) WO2017215723A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102454777B1 (ko) * 2016-06-17 2022-10-14 드러그 딜리버리 솔루션즈 에이피에스 요독 가려움증의 치료에 사용하기 위한 제형
WO2023194400A1 (en) * 2022-04-06 2023-10-12 Mc2 Therapeutics Ltd Topical formulation for use in the treatment or prevention of itchy dry skin
EP4681722A1 (en) * 2024-07-18 2026-01-21 Institut National de la Santé et de la Recherche Médicale Methods for the treatment of inflammatory skin diseases with urocanase inhibitor

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6573302B1 (en) * 1999-09-29 2003-06-03 Medical Merchandising, Inc. Cream utilizing capsaicin
WO2009103959A2 (en) * 2008-02-20 2009-08-27 The University Of Manchester Medicament
US20110217277A1 (en) * 2008-11-07 2011-09-08 Laboratoires Expanscience Drug or dermatological composition containing an avocado peptide extract for treating and preventing pruritus
US20140178458A1 (en) * 2011-08-18 2014-06-26 Evonik Industries Ag Medicinal skin protection composition with an active ingredient combination which improves the skin barrier
US20150252035A1 (en) * 2012-07-06 2015-09-10 Duke University Activation of trpv4 ion channel by physical stimuli and critical role for trpv4 in organ-specific inflammation and itch

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4025645A (en) 1976-01-27 1977-05-24 Jelenko Iii Carl Non-steroid topical agent for alleviating inflammation in mammals
US5811446A (en) 1997-04-18 1998-09-22 Cytos Pharmaceuticals Llc Prophylactic and therapeutic methods for ocular degenerative diseases and inflammations and histidine compositions therefor
US20060211754A1 (en) 2005-03-16 2006-09-21 Yu Ruey J Compositions comprising N-propanoyl derivatives of amino acids, aminocarbohydrates and derivatives thereof
US20070065396A1 (en) 2005-09-21 2007-03-22 Tracie Martyn International, Llc Topical macqui berry formulation
JP5168996B2 (ja) * 2007-04-13 2013-03-27 味の素株式会社 アミノ酸類高配合防腐水溶液
FR2916351B1 (fr) 2007-05-22 2012-12-07 Galderma Res & Dev Composition pharmaceutique comprenant au moins deux composes choisis parmi l'acide pyrrolidone-5-carboxylique, la citrulline, l'arginine et l'asparagine et leur utilisation dans le traitement de la dermatite atopique
US20090017129A1 (en) 2007-07-13 2009-01-15 Ma Or Ze Ev Dead Sea minerals enriched anti-inflammatory pharmaceutical composition for treatment of cutaneous dryness, itching, peeling and tightness, especially in hemodialysis patients and preparation and treatment methods thereof
US8337820B2 (en) 2008-02-13 2012-12-25 Bart Nieuwenhuijsen Composition of a water-soluble sunscreen preparation for acne rosacea
EP2373583A1 (en) 2008-07-23 2011-10-12 Fze Engsl A combined solid waste, carbon dioxide quicklime sparging, brine water, and reverse osmosis/ion exchange processes for the production of soda chemicals
NZ595775A (en) 2008-12-26 2013-07-26 Glenmark Pharmaceuticals Sa Fused imidazole derivatives as trpv3 antagonist
KR100953515B1 (ko) * 2009-08-28 2010-04-21 전북대학교산학협력단 피부 가려움증 개선을 위한 조성물
US20160008297A1 (en) 2012-08-23 2016-01-14 B.R.A.I.N. Biotechnology Research And Information Network Ag Compounds for preventing, reducing and/or alleviating itchy skin condition(s)
CN103908467B (zh) * 2013-01-05 2017-02-08 西藏博睿生物科技有限公司 一种药物组合物及制剂
WO2016086280A1 (pt) * 2014-12-04 2016-06-09 Cardoso De Gouveia Alberto Composição dermatológica e seu uso
KR102454777B1 (ko) 2016-06-17 2022-10-14 드러그 딜리버리 솔루션즈 에이피에스 요독 가려움증의 치료에 사용하기 위한 제형

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6573302B1 (en) * 1999-09-29 2003-06-03 Medical Merchandising, Inc. Cream utilizing capsaicin
WO2009103959A2 (en) * 2008-02-20 2009-08-27 The University Of Manchester Medicament
US20110217277A1 (en) * 2008-11-07 2011-09-08 Laboratoires Expanscience Drug or dermatological composition containing an avocado peptide extract for treating and preventing pruritus
US20140178458A1 (en) * 2011-08-18 2014-06-26 Evonik Industries Ag Medicinal skin protection composition with an active ingredient combination which improves the skin barrier
US20150252035A1 (en) * 2012-07-06 2015-09-10 Duke University Activation of trpv4 ion channel by physical stimuli and critical role for trpv4 in organ-specific inflammation and itch

Also Published As

Publication number Publication date
AU2020202785A1 (en) 2020-05-14
EP3471720B1 (en) 2024-12-04
EP4397368A2 (en) 2024-07-10
CA3026620C (en) 2022-09-20
KR20220143149A (ko) 2022-10-24
US20210000796A1 (en) 2021-01-07
US10806721B2 (en) 2020-10-20
ES3006940T3 (en) 2025-03-19
RU2018146294A3 (cg-RX-API-DMAC7.html) 2020-09-08
KR20240100484A (ko) 2024-07-01
BR112018076229A2 (pt) 2019-03-26
RU2018146294A (ru) 2020-07-17
CN109414430A (zh) 2019-03-01
JP2022187022A (ja) 2022-12-15
CA3026620A1 (en) 2017-12-21
WO2017215723A1 (en) 2017-12-21
EP3471720C0 (en) 2024-12-04
JP2022048311A (ja) 2022-03-25
EP3471720A1 (en) 2019-04-24
EP3471720A4 (en) 2020-02-05
JP7220316B2 (ja) 2023-02-09
JP2019518084A (ja) 2019-06-27
AU2017283511A1 (en) 2019-01-17
EP4397368A3 (en) 2024-10-16
US20190321336A1 (en) 2019-10-24
JP7019684B2 (ja) 2022-02-15
KR102454777B1 (ko) 2022-10-14
CN109414430B (zh) 2022-11-01
CN115671098A (zh) 2023-02-03
AU2020202785B2 (en) 2022-02-24
KR20190020022A (ko) 2019-02-27

Similar Documents

Publication Publication Date Title
AU2006245283B2 (en) Compositions and methods for treating hyperproliferative epidermal diseases
JP7220316B2 (ja) 尿毒症性掻痒症の治療に使用するための製剤
JP5732471B2 (ja) 溶媒混合物およびビタミンd誘導体から成る医薬品組成物または類似体
EP1476195B1 (en) Enhancement of the action of central and peripheral nervous system agents
US9006292B2 (en) Metadichol® liquid and gel nanoparticle formulations
EP3482761B1 (en) Compositions comprising cromoglicic acid for the treatment of dermatitis
JP5460766B2 (ja) 外用医薬組成物
JP2008069109A (ja) 外用医薬組成物
EP4504166B1 (en) Topical formulation for use in the treatment or prevention of itchy dry skin
JP2005170913A (ja) 抗真菌性外用組成物
PL234378B1 (pl) Kompozycja emulsyjna cefazoliny o działaniu przeciwłuszczycowym

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)